WallStSmart

Becton Dickinson and Company (BDX)vsLeMaitre Vascular Inc (LMAT)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Becton Dickinson and Company generates 8573% more annual revenue ($22.23B vs $256.28M). LMAT leads profitability with a 24.3% profit margin vs 5.1%. BDX appears more attractively valued with a PEG of 1.11. BDX earns a higher WallStSmart Score of 65/100 (B-).

BDX

Strong Buy

65

out of 100

Grade: B-

Growth: 6.0Profit: 5.0Value: 6.0Quality: 5.0
Piotroski: 6/9Altman Z: 1.49

LMAT

Buy

63

out of 100

Grade: C+

Growth: 8.0Profit: 8.0Value: 2.7Quality: 8.5
Piotroski: 4/9Altman Z: 3.16
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

BDXUndervalued (+9.9%)

Margin of Safety

+9.9%

Fair Value

$200.45

Current Price

$151.16

$49.29 discount

UndervaluedFair: $200.45Overvalued
LMATSignificantly Overvalued (-61.0%)

Margin of Safety

-61.0%

Fair Value

$54.53

Current Price

$94.48

$39.95 premium

UndervaluedFair: $54.53Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDX2 strengths · Avg: 8.0/10
Price/BookValuation
1.7x8/10

Reasonable price relative to book value

EPS GrowthGrowth
28.6%8/10

Earnings expanding 28.6% YoY

LMAT4 strengths · Avg: 8.8/10
Altman Z-ScoreHealth
3.1610/10

Safe zone — low bankruptcy risk

Profit MarginProfitability
24.3%9/10

Keeps 24 of every $100 in revenue as profit

Operating MarginProfitability
26.7%8/10

Strong operational efficiency at 26.7%

EPS GrowthGrowth
41.7%8/10

Earnings expanding 41.7% YoY

Areas to Watch

BDX4 concerns · Avg: 3.0/10
P/E RatioValuation
25.2x4/10

Moderate valuation

Return on EquityProfitability
4.7%3/10

ROE of 4.7% — below average capital efficiency

Profit MarginProfitability
5.1%3/10

5.1% margin — thin

Altman Z-ScoreHealth
1.492/10

Distress zone — elevated risk

LMAT2 concerns · Avg: 3.0/10
P/E RatioValuation
34.8x4/10

Premium valuation, high expectations priced in

PEG RatioValuation
2.632/10

Expensive relative to growth rate

Comparative Analysis Report

WallStSmart Research

Bull Case : BDX

The strongest argument for BDX centers on Price/Book, EPS Growth. PEG of 1.11 suggests the stock is reasonably priced for its growth.

Bull Case : LMAT

The strongest argument for LMAT centers on Altman Z-Score, Profit Margin, Operating Margin. Profitability is solid with margins at 24.3% and operating margin at 26.7%. Revenue growth of 11.2% demonstrates continued momentum.

Bear Case : BDX

The primary concerns for BDX are P/E Ratio, Return on Equity, Profit Margin.

Bear Case : LMAT

The primary concerns for LMAT are P/E Ratio, PEG Ratio.

Key Dynamics to Monitor

BDX profiles as a value stock while LMAT is a mature play — different risk/reward profiles.

LMAT carries more volatility with a beta of 0.60 — expect wider price swings.

LMAT is growing revenue faster at 11.2% — sustainability is the question.

BDX generates stronger free cash flow (546M), providing more financial flexibility.

Bottom Line

BDX scores higher overall (65/100 vs 63/100). Both earn "Strong Buy" and "Buy" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Becton Dickinson and Company

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

Becton, Dickinson and Company, also known as BD, is an American multinational medical technology company that manufactures and sells medical devices, instrument systems, and reagents. BD also provides consulting and analytics services in certain geographies.

Visit Website →

LeMaitre Vascular Inc

HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA

LeMaitre Vascular, Inc. designs, markets, sells, services and supports medical devices and implants for the treatment of peripheral vascular diseases worldwide. The company is headquartered in Burlington, Massachusetts.

Want to dig deeper into these stocks?